Table 2.
In vitro potency of nirmatrelvir for inhibiting the SARS-CoV-2 mutant Mpro activity in a FRET assay
| Mutant enzyme | Ki (nM) geomean | Ki (nM) lower 95% CI | Ki (nM) upper 95% | n | p-valuea to wildtype Ki |
|---|---|---|---|---|---|
| G15S | 4.07 | 2.62 | 6.32 | 4 | 0.0002 |
| K90R | 1.05 | 0.19 | 5.82 | 5 | 0.371 |
| P132H | 0.635 | 0.179 | 2.25 | 4b | 0.074 |
| Wildtype | 0.933 | 0.471 | 1.85 | 9b | NA |
a
p-value calculated as a t test statistic for log Ki values compared to wildtype.
b
The n value represents the number of Ki values used to determine the geomean and CI which is lower than the experiment count due to censoring, i.e., experimental values that are < are excluded from geomean calculation.